UCB's Global Corporate Website
Welcome to UCB in the United States
May 15
UCB Statement on COVID-19 Outbreak

Patients are at the heart of everything we do, and UCB is committed to helping those impacted by the novel coronavirus, COVID-19. This includes helping patients maintain access to and answering any questions about UCB medicines, as well as putting patient and community care first in all our actions during these uncertain times.

Check out the latest updates on UCB's response in the U.S. here.

The evolving COVID-19 pandemic has placed tremendous strain on medical healthcare systems worldwide as they focus on the ongoing extraordinary medical emergency. Taking this into consideration, UCB has taken measures to protect the patients we serve and others around the world.

We are committed to assuring reliable supply of medicines in every market where we have a commercial presence. Despite the rapid emergence of the novel coronavirus and the challenge presented to healthcare systems around the globe, UCB has not experienced shortages for any of our products due to this epidemic.

Since the onset of the coronavirus outbreak, UCB has been closely monitoring our supply chain for potential impact to the supply of our medicines around the world. UCB leverages strategic buffer stock along with multi-sourcing for key materials in our global supply chain to mitigate the impact of supply disruptions due to events such as the current coronavirus outbreak.

Our global manufacturing and distribution network continues to be fully operational and UCB remains in constant contact with our global network of key suppliers, manufacturing partners, and distributors to identify potential risks and take appropriate measures to avoid any disruption. At this time, we do not anticipate any supply disruption of our products. As this global situation evolves, we will continue to take the steps necessary to safeguard the reliable supply of our medicines.

Clinical Trials
In March 2020, the evolving COVID-19 pandemic led UCB to halt recruitment into ongoing clinical studies and delay all new study starts. This decision was taken in the interest of public health safety and to help reduce the strain on healthcare systems across the world during a time of extraordinary medical emergency. As from mid-May 2020, UCB began to restart clinical study recruitment, including new study starts, at clinical trials sites that meet our restart criteria.

UCB continues to proactively monitor the COVID-19 situation and will take any necessary precautionary steps in the interest of public health. Healthcare professionals and patients with questions related to UCB medicines can contact UCBCares / UCB Medical Information teams across the globe. Contact details can be found here.

Additional Info
We have suspended all proactive face-to-face activity between our field-based personnel and Health Care Providers. We have asked that our employees remain responsive to any needs that may arise in the local areas and provide support for patients and stakeholders, if requested and feasible.

In addition, ucbCARES stands ready to help anyone impacted by COVID-19 find answers to their questions and ensuring they receive the respect and care they deserve during this concerning time. Contact ucbCARES at +1-844-599-CARE (2273), via email at UCBCares@ucb.com, or visit: Patients

As we navigate this unpredictable situation together as a global community, UCB’s commitment to supporting patients living with severe, chronic diseases remains unchanged. From our team at UCB, our hearts go out to all those affected by COVID-19, and we are here to help.

Share:linkedin| twitter| email